Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:

NCT ID: NCT03731728 Not yet recruiting - Clinical trials for Major Depressive Disorder

Group CBT and Exercise in Management of Depression

Start date: January 2019
Phase: N/A
Study type: Interventional

INTRODUCTION: There is strong evidence indicating the effectiveness of Cognitive-Behavior Therapy (CBT) in the management of Major Depressive Disorder (MDD) and some clinical trials indicating physical exercise (PE) as an effective treatment for the disorder. However, few studies have evaluated the effect of group CBT or PE compared to wait-listing to receive treatment as usual (TAU) in the management of MDD. This study will evaluate and compare the effectiveness of: 1) group CBT plus wait-listing for TAU; versus 2) group PE plus wait-listing for TAU; versus 3) only wait-listing for TAU in management of MDD. The investigators hypothesize that participants with MDD assigned to the group CBT or PE (plus wait-listed for TAU) arms of the study will achieve superior outcomes compared to participants only wait-listed for TAU. METHODS AND ANALYSIS: This is a prospective rater-blinded randomized controlled trial assessing the benefits for participants with MDD. 120 patients with MDD referred to Addiction and Mental Health (AMH) clinics in Edmonton Zone who are informed about the study and consent to participate will be randomly assigned to one of the 3 arms of the study: 1) 40 participants wait-listed for TAU will receive weekly sessions of group CBT for 14 weeks; 2) 40 participants wait-listed for TAU will receive PE 3 times a week for 14 weeks; and 3) 40 participants will only be wait-listed for TAU. All participants will be assessed at baseline, 7 and 14 weeks. Their assessments will cover primary outcomes including functional variables (recovery, quality of life, employment) and symptom variables (changes in depressive symptoms scores). Secondary client outcomes will be service variables (e.g. patient satisfaction with the service). The data will be analyzed using repeated measures and effect size analyses, and correlational analyses will be completed between measures at each time point. ETHICS AND DISSEMINATION: The study will be conducted in accordance with the Declaration of Helsinki (Hong Kong Amendment) and Good Clinical Practice (Canadian Guidelines). Written informed consent will be obtained from each subject. The study has received ethical clearance from Health Ethics Research Board of the University of Alberta (Ref. # Pro 00080975) and operational approval from the provincial health authority (AHS # 43638). The results will be disseminated at several levels, including patients, practitioners, academics/researchers, and healthcare organizations.

NCT ID: NCT03731481 Completed - Obesity Clinical Trials

Virtual Lifestyle Medicine Comparative Effectiveness Research

Start date: May 31, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of two online Lifestyle Medicine programs. Participants will be randomized by residence, urban vs. rural, into one of two Lifestyle Medicine programs.

NCT ID: NCT03730974 Not yet recruiting - Clinical trials for Insomnia Due to Mental Disorder

Ball Blankets on Insomnia in Depression in Outpatient Clinics

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The objective of the study is to examine the efficacy of Protac Ball BlanketsTM (PBB) and specifically if the PBB will extend the total sleep time of patients with insomnia due to depression in two psychiatric outpatient clinics at Aarhus University Hospital and Odense University Hospital. Furthermore, it will be examined whether the PBB will reduce the sleep onset latency, number of awakenings, need for sedatives and hypnotics, the self reported symptoms of depression and anxiety and improve the quality of sleep. 45 with depression and insomnia who receive outpatient treatment will be included in this study. The study is a randomized cross-over study. The data collection period lasts four weeks. Data will be collected using actigraphs, sleep diaries and questionnaires.

NCT ID: NCT03730064 Recruiting - Depression Clinical Trials

Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression

Start date: November 1, 2018
Phase: Early Phase 1
Study type: Interventional

We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will have two different brain scans (MRI and PET scan). You will also have an experimental treatment for your depression named N-acetyl cysteine (NAC). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder. Please contact us if you are interested in participating. Up to $600 in compensation if you are eligible and choose to participate. Up to 6 months of treatment for depression at no cost to you.

NCT ID: NCT03727659 Active, not recruiting - Depression Clinical Trials

CONNECT for Depressed Cannabis Users Trial

CONNECT
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to test the usefulness of a computer-assisted intervention for depressed cannabis users by combining peer and therapist social network support via Facebook that uses the techniques of cognitive behavioral therapy and motivational enhancement therapy (CBT/MET) to help with relapse prevention skills, reduce cannabis use and depressive symptoms, and improve treatment adherence. All participants will receive 10 weeks of the computer assisted intervention which includes weekly 60 minute (1 hour) sessions. All participants will also be part of a secret Facebook group (CONNECT). The goal of this secret Facebook group is to reinforce the knowledge and skills taught in the computer assisted intervention and to provide social support.

NCT ID: NCT03726658 Not yet recruiting - Clinical trials for Major Depressive Disorder

AGN-241751 in the Treatment of Major Depressive Disorder

Start date: November 6, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder

NCT ID: NCT03726138 Not yet recruiting - Anxiety Clinical Trials

The Association of Sleep and Psychological Symptoms With Prognosis of MSK Pain in Danish General Practice

Start date: November 1, 2018
Phase:
Study type: Observational

Musculoskeletal (MSK) pain is a major public health concern. Approximately one in four consult their general practitioner (GP) with a musculoskeletal problem during the course of a year, making it the largest diagnostic group. Modifiable factors including affective disorders (e.g. anxiety and depressive symptoms) and sleep problems may be important prognostic factors for MSK pain. However, there is a lack of prospective research examining the interaction between these conditions in patients with MSK pain in a GP-setting.

NCT ID: NCT03722095 Recruiting - Clinical trials for Major Depressive Disorder

Research on the Effects of Combined Neurostimulation Protocols on Stress Reactivity

Start date: October 16, 2018
Phase: N/A
Study type: Interventional

The study examines the effects of the combined use of two different non-invasive brain stimulation (NIBS) techniques targeting the DLPFC on stress reactivity.

NCT ID: NCT03721900 Not yet recruiting - Clinical trials for Major Depressive Disorder

Ketamine for Major Depressive Disorder

Start date: November 15, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

NCT ID: NCT03721588 Completed - Clinical trials for Depressive Disorder, Major

Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD

Start date: September 1, 2015
Phase:
Study type: Observational

In the presence of attention deficit hyperactivity disorder (ADHD) together with additional psychiatric diseases, the treatment process and prognosis of both ADHD and psychiatric comorbidity are adversely affected. The aim of this study is to compare the characteristics concerning the suicidal behavior of the patients with major depressive disorder (MDD) who have (ADHD+) or do not have (ADHD-) adult ADHD comorbidity and their responses to depression treatment. 96 inpatients were included in the study. Socio-demographic data form, Hamilton Depression Scale (HDRS), Wender Utah Rating Scale (WURS), Adult ADD/ADHD DSM IV- Based Diagnostic Screening and Rating Scale (A-ADHD), Personal and Social Performance Scale (PSP) were applied to the cases. In the study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior. For these reasons, clinicians should be careful during ADHD and depression management in adults.